The GLCC consists of 41 patient advocacy groups based in 40 countries and it is dedicated to improving disease outcomes in lung cancer. In 2020 (pre-COVID), they had lung cancer patients from around the world complete an online survey to compare patient experiences between countries. The survey asked questions about demographics, diagnosis, interventions, and experiences. In 2021, the GLCC repeated the survey, adding questions about the emotional and physical impacts of their diagnosis, the impact of COVID-19, and how patients prefer to receive information. The findings of this 2021 survey were presented by Ms Jackie Fenemore (Lung Cancer Nursing, UK).
Although most respondents reported satisfaction with the time to diagnosis, a significant proportion of patients felt that their diagnoses had been unnecessarily delayed. In most countries, some patients felt that they were not as involved in decision-making about their treatment as they would have preferred. The proportion of patients who felt that they had been treated with dignity and respect varied.
Common emotional themes were anxiety, shame, fear of relapse, financial concerns, and worries for loved ones. Family and friends comprised the main sources of emotional support. Some respondents reported discomfort with seeking emotional support from their treatment team; some did not realise that this was an option. Most patients had undergone virtual consultations; they reported both advantages and disadvantages to this shift.
GLCC hopes that their findings will help to guide policymakers and healthcare practitioners who treat patients with lung cancer. More information can be found at https://www.lungcancercoalition.org/.
- Fenemore J. Patients’ Experiences During COVID-19: Insights from the Second Global Lung Cancer Coalition Patient Experience Survey. MA 05.01, WCLC 2021, 8–14 September.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Atezolizumab promising for treating NSCLC brain metastases Next Article
COVID-19 sees decreased lung cancer diagnoses and use of support services in US »
« Atezolizumab promising for treating NSCLC brain metastases Next Article
COVID-19 sees decreased lung cancer diagnoses and use of support services in US »
Table of Contents: WCLC 2021
Featured articles
Atezolizumab promising for treating NSCLC brain metastases
Novel Therapy Approaches
Atezolizumab promising for treating NSCLC brain metastases
Interim results of nivolumab + rucaparib in SCLC
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
Real-world data shows inferior survival compared with IMpower150 results
NSCLC metastases also benefit from nivolumab + ipilimumab + chemo
Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma
COVID-19
COVID-19 sees decreased lung cancer diagnoses and use of support services in US
Experiences of lung cancer patients during COVID-19: survey finds room for improvement
Evidence-Based Advocacy
GLCC survey: Increased demand for patient-support services during COVID-19 pandemic
Lung Cancer Europe patient survey identifies gaps in lung cancer care
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
Response Predictors
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
Genomic profiling of NSCLC may be predictive of immunotherapy response
New preoperative classification scheme proposed for oligometastatic NSCLC
Prognostic factors in immunotherapy for advanced lung cancer
Related Articles
November 25, 2020
Consolidation ipilimumab and nivolumab in limited stage SCLC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy